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The Toll-like receptor 4 (TLR4) is a class I transmembrane receptor expressed on the surface of immune system cells. TLR4 is
activated by exposure to lipopolysaccharides derived from the outer membrane of Gram negative bacteria and forms part of
the innate immune response in mammals. Like other class 1 receptors, TLR4 is activated by ligand induced dimerization, and
recent studies suggest that this causes concerted conformational changes in the receptor leading to self association of the
cytoplasmic Toll/Interleukin 1 receptor (TIR) signalling domain. This homodimerization event is proposed to provide a new
scaffold that is able to bind downstream signalling adaptor proteins. TLR4 uses two different sets of adaptors; TRAM and TRIF,
and Mal and MyD88. These adaptor pairs couple two distinct signalling pathways leading to the activation of interferon
response factor 3 (IRF-3) and nuclear factor kB (NFkB) respectively. In this paper we have generated a structural model of the
TLR4 TIR dimer and used molecular docking to probe for potential sites of interaction between the receptor homodimer and
the adaptor molecules. Remarkably, both the Mal and TRAM adaptors are strongly predicted to bind at two symmetry-related
sites at the homodimer interface. This model of TLR4 activation is supported by extensive functional studies involving site
directed mutagenesis, inhibition by cell permeable peptides and stable protein phosphorylation of receptor and adaptor TIR
domains. Our results also suggest a molecular mechanism for two recent findings, the caspase 1 dependence of Mal signalling
and the protective effects conferred by the Mal polymorphism Ser180Leu.
Citation: Nu´n˜ez Miguel R, Wong J, Westoll JF, Brooks HJ, O’Neill LAJ, et al (2007) A Dimer of the Toll-Like Receptor 4 Cytoplasmic Domain Provides
a Specific Scaffold for the Recruitment of Signalling Adaptor Proteins. PLoS ONE 2(8): e788. doi:10.1371/journal.pone.0000788
INTRODUCTION
In humans and other vertebrates initial responses to infection by
pathogenic microorganisms such as viruses and bacteria are
mediated by a highly developed innate immune response[1].
Pattern recognition receptors (PRRs) expressed by immune system
cells such as macrophages and dendritic cells are able to detect
conserved microbial structures. These cells then generate the
innate immune responses that are required to fight the infection
and promote the development of adaptive immunity. The Toll-like
receptors (TLRs) are an important group of PRRs that respond to
a range of microbial products such as lipopeptides and non-self
nucleic acids [2]. The TLRs are type I transmembrane receptors
and consist of an extracellular domain made up mainly of leucine
rich repeat motifs, a single transmembrane spanning segment and
a globular cytoplasmic domain, the Toll/interleukin 1 receptor
domain (TIR) [3]. There are ten Toll-like receptors encoded in the
human genome and each of these respond to specific microbial
products.
One of the most important innate immune stimuli is
lipopolysaccharide (LPS) or endotoxin found in the outer
membrane of Gram-negative bacteria [4]. LPS is one of the most
powerful immunostimulators known and is responsible not only for
the induction of innate immunity but also for the dangerous
condition endotoxic shock which often develops during Gram
negative septicaemia. Endotoxic shock is a severe inflammatory
disease that leads rapidly to multi organ failure and death. This
condition accounts for about 200,000 deaths per annum in Europe
and thus understanding the mechanism of action of LPS mediated
immune activation is an important objective in medical research
[5]. In 1998 TLR4 was identified as the signalling receptor for
LPS. Mice that lack functional TLR4 are hyposensitive to LPS
and consequently more sensitive to infection by Gram negative
bacteria [6]. Subsequent studies showed that MD-2, a co-receptor
protein of TLR4, was also essential for LPS induced signalling
[7,8]. MD-2 is a member of a small class of lipid binding proteins
and interacts directly with the lipid A moiety of LPS [9,10].
Like other class I receptors the initial step in signal transduction
by TLR4 involves dimerization or oligomerization of two receptor
chains induced by binding of MD-2 to the lipid A moiety of LPS
[11]. This in turn probably causes protein conformational changes
in the receptor resulting in the association of two receptor TIR
domains (Figure 1) [12]. Alternatively, the receptor may be present
in the cell as a preformed but inactive dimer and ligand binding
may cause reorientation of the TIR domains. Consistent with this
idea, a recent study using FRET (fluorescence resonance energy
transfer) microscopy showed that the TLR9 TIR domains undergo
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a large positional change on ligand binding [13]. In either case
association of the receptor TIRs would provide a new scaffold that
allows the recruitment of specific adaptor proteins to form a post-
receptor signalling complex. There are five adaptor proteins, all of
which contain TIR domains, that function in TLR signalling;
MyD88 (Myeloid differentiation primary response protein 88),
Mal (MyD88 adaptor like; also known as TIRAP), TRIF (TIR
domain-containing adaptor protein inducing interferon-b; also
known as TICAM1), TRAM (TRIF-related adaptor molecule;
also known as TICAM2), and SARM (sterile a- and armadillo-
motif-containing protein) [14]. The TIR domain forms into an
a2b structure and the sequence conservation observed reflects
the structural requirements of this fold [15]. On the other hand,
the loops that connect the secondary structure elements of the TIR
domain and the surface electrostatic properties are more variable
and these properties may confer specificity for homo- and
heterotypic interactions between different TIR domains [16].
Unlike the other TLRs, activated TLR4 signals via two
distinct sets of adaptor proteins, Mal and MyD88, and TRAM
and TRIF [17,18] (see Figure 1). For each pathway Mal and
TRAM are thought to engage directly with the TLR4 receptor
dimer and subsequently act as ‘bridging adaptors’ for the
recruitment of MyD88 and TRIF respectively. Mal is required
for rapid activation of the NFkB transcription factor and the
production of pro-inflammatory cytokines such as TNFa and
IL12. The TRAM adaptor on the other hand stimulates
a different pathway leading to activation of the interferon
response factor, IRF-3. IRF-3 induces expression of a distinct
set of genes to NFkB, such as interferon b and the chemokine
RANTES. It is not known whether a single activated TLR4
dimer can recruit both TRAM and Mal simultaneously or
whether binding is mutually exclusive.
In this paper we have used modelling, docking and mutagenesis
studies to investigate the nature of the initial TLR4 receptor
dimer-‘bridging adaptor’ complexes. We show that both Mal and
TRAM are strongly predicted to bind at the interface of a TLR4
TIR homodimer, a result consistent with multiple other studies
using mutagenesis of receptor and adaptor TIRs and blocking
peptides.
RESULTS
Predicted structure of the TLR4 TIR domain
homodimer and the Mal and TRAM adaptors
The structure of the receptor TIR domains from TLR1 and 2 was
solved previously by X-ray crystallography [19]. These modules
behave as monomers in solution and the packing of the molecules
in the crystal lattice does not suggest a likely arrangement for the
functional homodimer generated during receptor activation. More
recently in the course of a structural genomics project, the TIR
Figure 1. The TLR4 signalling pathway. (A) Overview of the TLR4 signalling pathway. Both the NF-kB and the interferon pathways are induced by
stimulation with lipopolysaccharide. Adapted from [2,3]. (B) Mechanism of signal transduction by TLR4. The curved ectodomains (ECD) are illustrated
in light blue and the co-receptor protein MD-2 in grey. The TIR domains are shown in yellow and red respectively. M = membrane, L = LPS. (i) Prior to
activation, receptor molecules are able to diffuse in the membrane and may form transient dimers. The ectodomains are rigidly connected to the
cytoplasmic TIRs by the transmembrane helix. (ii) Receptor dimerization following activation by LPS binding to MD2. By analogy with Drosophila Toll
(see [45]), which is activated by a dimeric protein ligand, the receptor complexes are likely to be symmetrical. Conformational rearrangements
constrain the TIR domains to interact through equivalent surfaces forming a symmetrical dimer. (iii) The dimerized TIRs provide a new molecular
surface that can bind to the ‘bridging adaptor’ molecules TRAM and Mal with high affinity. Interaction with the downstream adaptors TRIF and
MyD88 leads to NFkB and IRF3 mediated signalling respectively.
doi:10.1371/journal.pone.0000788.g001
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domain of TLR10 has been solved (http://sgc.utoronto.ca/SGC-
WebPages/StructureDescription/2J67.php). In contrast to TLR1
and 2, the TLR10 TIR domain is present as a dimer in the
asymmetric unit. The molecules are related by a two-fold axis of
symmetry and there is an extensive dimer interface. In addition,
the region of the TIR domain involved in dimer formation
includes a surface structural element called the BB-loop that links
the second b-sheet to the second a-helix. The BB loop is thought
to be important for homodimer formation because mutations of
a conserved proline residue inactivate signalling and exert
dominant negative effects, indicating the formation of non-
functional heterodimers of the wild-type and mutant receptor
chain. Thus it is likely that the TLR10 TIR structure represents
a physiologically relevant conformation.
In light of this, and the widely held view that signal induced
dimerization of the receptor cytoplasmic domains is required for
signalling [12], we decided to model the TLR4 TIR domain as
a homodimer, reasoning that this structure would approximate the
configuration adopted in the activated receptor complex. This
approach allows significant advances to be made in the
interpretation of our modelling results over previous work in
which the TLR4 TIR was modelled as a monomer [16]. The
crystal structures of TLR1 and TLR2 (Pdb: 1FYV and 1FYW)
together with the recently released crystal structure of the human
TLR10 dimer (Pdb: 2J67) were used as templates to build the
TLR4 structural model (Figure 2). In the alignments used for the
modelling sequence identity between TLR4 and TLR1, TLR2
and TLR10 was 35.0%, 40.5% and 35.0%, respectively. The
secondary structure of the modelled TLR4 TIR domain is similar
to that of the templates. It is predicted to contain five b strands and
six a helices, with the BB loop adopting a similar conformation to
that in the template structures (Figures 2, 3A and 3B). Analysis of
the structural model of the TLR4 dimer reveals that 94.2% of the
phi-psi dihedral angles are found in the most favourable regions of
the Ramachandran plot. The remaining 5.8% are found within
the allowed regions. This highlights the excellent geometry of the
model. Verify3D [20] reports no values below 0.21, further
indicating that all the residues are located in favourable structural
environments. The JOY output also shows that the residues in the
model are in environments similar to those of the templates
(Figure 2).
The surface area buried at the dimer interface of the TLR4
homodimer has contributions of 657 A˚2 and 665 A˚2 from each of
the two protomers. Table 1 lists the 18 residues that make van der
Waals contacts with residues from the other chain in the dimer
interface. Interestingly, some interactions are non-reciprocal. For
example, Arg745 from chain A makes an interaction that buries
42.4 A˚2 of surface but the corresponding residue in chain B buries
only 8.6 A˚2. Similarly, Arg780 from chain A buries a surface of
30.8 A˚2 whilst the same residue from chain B does not interact.
Weak inter-subunit electrostatic interactions are also observed.
The strongest is between Glu750 from one chain and Arg780 from
the other. However, the distance between charged atoms is 9.6 A˚.
Significantly the BB loops from the two protomers also interact
with each other. In particular, the residue Phe712 from each
subunit forms an aromatic interaction with one another. In-
terestingly, the dimer has a flat but slightly curved surface
(Figure 3B – side view) which may be the top (or membrane
proximal) surface of the structure (see discussion).
We have also generated high quality models of the Mal and
TRAM adaptor TIR domains (Figure 3C, D), using the crystal
structures of TLR1 and 2 as templates (Figure 2). In the
alignments used Mal displays amino acid sequence identity with
TLR1 and TLR2 of 21.1% and 23.0%, respectively. As expected
the secondary structure of the Mal TIR domain is similar to that of
the templates with the exception of a nine amino acid deletion
before the start of the 4th helical segment (alignment position 114
to 122 in Figure 2). This deletion results in structural distortion
and loss of the aD helix and a small b strand. The model of the
Mal TIR domain also has good geometry. None of its phi-psi
dihedral angles are found within disallowed regions of the
Ramachandran plot, whilst 90.6% are in geometrically favoured
regions. The JOY and Verify3D outputs show that the environ-
ments of residues in the model of Mal are similar to those of the
templates and are not energetically unfavourable (Figure 2).
Overall the structure of Mal is a four-stranded b sheet surrounded
by five a helices in which the BB loop adopts a fixed conformation
similar to that seen in TLR1 and 2. A similar strategy was used to
model the structure of the TRAM adaptor. In this instance the
amino acid sequence identity between the modelled regions of
TRAM and TLR1 and TLR2 are 15.5% and 15.9%, respectively.
With the exception of a ten amino acid insertion before the last
small b strand (alignment position 136 to 145 in Figure 2) the
secondary structure of the TRAM TIR domain is similar to that of
the templates. The phi-psi dihedral angles of the TRAM model
show good geometry. The Ramachandran plot contains 88.5% in
the most favourable regions, 10.9% in allowed regions and only
a single residue (0.6%) in disallowed regions. As with Mal and
TLR4 the residues in the TRAM model are predicted to be in
structurally favourable environments.
The MAL and TRAM adaptors are predicted to bind
at the TLR4 dimer interface
We have used GRAMM [21], a molecular docking programme
that uses shape complementarity to assess the interaction of
protein molecules, to probe the likely binding sites in the TLR4
dimer for the adaptors Mal and TRAM (Figure 4A, B).
Consideration of TLR4 as a dimer creates a more physiologically
relevant receptor docking template compared with earlier studies
in which the TLR4 receptor was modelled as a monomer [16].
Remarkably, the 100 best low resolution docking solutions for Mal
lie at the TLR4 dimer interface indicating that dimer formation
creates two specific symmetry related binding sites for this
molecule. The TRAM adaptor is predicted to bind to the same
site as Mal. The interaction surfaces on the TLR4 dimer interface
are at either side of the structure rather than at the top, a region
that would be sterically hindered by the membrane.
We then carried out high resolution docking experiments using
the programme PyDock [22]. These experiments were guided
through the use of new, and previously published, information
from mutagenesis studies. In particular we took account of
mutants located on the side surface of the dimer (His728Asp,
Trp757Ala, Gln683Ala, IleIle723-724AlaAla, His724Ala,
GlyPhe726-728AlaAla, Gln758Ala, Arg763Ala; see Table 2, 3;
and ref [23]). We also considered the impact of reported
contributions from Mal (BB loop residues and a tyrosine
phosphorylation site, Tyr86, located close to the BB loop, see
discussion). The high resolution model of the TLR4 homodimer
with Mal and TRAM bound is shown in Figure 4C with Mal in
magenta and TRAM in yellow.
The buried surface at the interface of the TLR4 dimer-Mal
complex constitutes 1824 A˚2 from the TLR4 dimer and 1761 A˚2
from Mal. There are 17 residues from TLR4 chain A and 28
residues from chain B that make contacts (DASA.1 A˚2) with 49
residues from Mal. Table 4 shows those residues that produce the
strongest van der Waals interactions (DASA.40 A˚2) in the
complex interface. For TLR4 this is Trp757, and for Mal
TLR4 TIR Signalling
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Glu167. Seven hydrogen bonds are present in the interface of the
TLR4 dimer-Mal complex, donated by three residues from each
TLR4 chain and six residues from Mal. This includes a double
hydrogen bond between TLR4 His728 and Mal Thr166. Strong
electrostatic interactions are present between charged residues
from both components of the complex. The strongest salt bridge is
between the TLR4 Arg763 and Mal Glu167. Also important is the
ion pair between TLR4 Lys819 and Mal Glu167.
The interface of the TLR4 dimer-TRAM complex results in
a buried surface of 1729 A˚2 from the TLR4 dimer and 1805 A˚2
from TRAM. TLR4 chain A and B contribute 33 and 9 residues
respectively, which form contacts (DASA.1 A˚2) with 43 residues
from TRAM. Table 5 shows those residues that produce strong
van der Waals interactions (DASA.40 A˚2) in the complex
interface. As with the Mal complex, TLR4 Trp757 makes the
strongest interaction with TRAM, whilst TRAM Asn 159 interacts
most strongly with TLR4. In this complex only three hydrogen
bonds are present in the interface. TLR4 chain A donates three
residues and TRAM two, of which one, Asp164, produces two
strong hydrogen bonds. Strong electrostatic interactions are
observed between charged residues from both components of
the complex. Salt bridges are formed between TLR4 Glu824 and
TRAM Arg231 and TLR4 Glu685 and TRAM Arg119. Also
important is the ion pair between TLR4 Arg780 and TRAM
Glu75.
We next used the FPSPD program (see Methods) to predict
functional sites in TLR4, Mal and TRAM. The patterns found for
TLR4 were: residues 677–698, 705–730, 734–759 and 795–815.
The first functional pattern 677–698 contains residues involved in
Mal binding (Table 4). Pattern 705–730, which includes the BB
loop, possesses residues for homodimerization, and TRAM
binding (Tables 1 and 5) and pattern 734–759 is implicated in
homodimerization and Mal binding (Tables 1 and 4). Finally,
pattern 795–815 does not contribute to any of the interactions
identified in this study but may represent a binding site for a second
adaptor molecule such as MyD88. In the case of Mal, the
Figure 2. Structure based sequence alignments of TIR domains. The program JOY was used to annotate the alignments for TLR1, TLR2 TLR4, TLR10,
Mal and TRAM. Numbers on top of amino acid sequences are alignment positions. The key to JOY annotations is as follows (a graphical version is
viewable as Table S1); solvent inaccessible – UPPER CASE; solvent accessible – lower case; a-helix – dark grey shaded; b-strand – mid-grey shaded; 310
helix – light grey shaded; hydrogen bond to main chain amide – bold; hydrogen bond to main chain carbonyl – underline; hydrogen bond to other
sidechain – tilde; disulphide bond – cedilla; positive w - italic; cis-peptide – breve.
doi:10.1371/journal.pone.0000788.g002
TLR4 TIR Signalling
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Figure 3. Structural modelling of the TLR4 TIR domain homodimer, Mal and TRAM. The BB loops of the two TLR4 protomers are coloured blue and
yellow respectively. For Mal and TRAM they are coloured green (A) TLR4 top view. (B) TLR4 side view. (C) Mal. (D) TRAM.
doi:10.1371/journal.pone.0000788.g003
Table 1. Interacting residues in the dimer interface of TLR4.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Residue Number Residue type Chain DASA (A˚2) Residue Number Residue type Chain DASA (A˚2)
682 Ser A 16.3 682 Ser B 9.5
708 His A 19.6 708 His B 31.8
709 Tyr A 88.5 709 Tyr B 75.0
712 Phe A 50.8 712 Phe B 45.0
714 Pro A 79.0 714 Pro B 79.4
715 Gly A 18.5 715 Gly B 15.4
716 Val A 7.0 716 Val B 8.2
717 Ala A 35.4 717 Ala B 50,2
718 Ile A 99.3 718 Ile B 99.6
719 Ala A 15.0 719 Ala B 23.1
743 Gln A 11.4 743 Gln B 5.7
744 Ser A 14.2 744 Ser B 31.5
745 Arg A 42.4 745 Arg B 8.6
747 Cys A 55.8 747 Cys B 71.0
748 Ile A 27.9 748 Ile B 33.8
750 Glu A 1.2 --- --- - ---
751 Tyr A 42.9 751 Tyr B 33.9
--- --- - --- 754 Ala B 4.9
--- --- - --- 755 Gln B 37.2
780 Arg A 30.8
doi:10.1371/journal.pone.0000788.t001..
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functional patterns predicted by FPSPD are: residues 89–104,
108–122, 121–139 and 146–169. All these are directly involved
in TLR4 binding except pattern 108–122. However, this one
is spatially close to the TLR4 pattern 795–815 in the TLR4
dimer-Mal complex. Thus these patterns could both contribute
to a binding site that is only formed after initial recruitment of
Mal. In the case of TRAM the patterns identified are: residues
72–94, 117–127, 136–164, 171–181 and 218–226. Patterns 72–94
and 136–164 have involvement in TLR4 binding, see (Table 5).
Only one residue from pattern 117–127 interacts with TLR4,
and neither pattern 171–181 nor 218–226 contain residues
that interact with TLR4. These regions may potentially be
involved in binding of a second adaptor, for example TRIF.
Interestingly, pattern 117–127 is spatially equivalent to the Mal
pattern 108–122.
In conclusion, this modelling study predicts that homodimer-
ization of the TLR4 TIR domain creates a scaffold for the
recruitment of adaptor molecules into a post receptor complex.
Remarkably the study predicts that the ‘BB’ loop structures of all
three molecules are critical determinants of binding specificity
(Figure 4C).
Functional studies of the TLR4, MAL and TRAM TIR
domains support the proposed mechanism of
receptor activation
Although experimental structural analysis of TLR4 has proved
difficult a number of studies have identified regions of the receptor
and adaptor TIRs that are important for signalling function. In
particular these studies have utilised mutagenesis, the use of cell
permeable blocking peptides and studies of Mal tyrosine
phosphorylation.
Table 2 summarises the results of mutagenesis studies on the
TIR domain of TLR4 and the effect that the mutations are
predicted to have on the receptor-adaptor complexes. This
includes previously unpublished data together with the results
reported by Ronni et al [23]. In general the effect of mutating
individual residues is variable, ranging from a substantial loss of
function, such as the BB loop proline residue, to partial or no loss
of signalling. Our analysis indicates that the mutants that impair
function can be grouped into three classes. The first are those such
as P714 that are likely to impair receptor homodimerization or
cause the formation of non-functional receptor dimers that are not
able to bind adaptors. These residues predominantly lie in two
discrete regions of the molecule, residues 708–718, containing the
BB-loop, and residues 744–755 which form the aC helix/CD loop.
The second group are residues that lie in the putative adaptor
binding surface created by the dimer interface. The modelling
study identifies two other surfaces that may be interaction sites
with adaptors or other protein factors involved in TLR4 signalling,
one on the sides of the dimer and one on the bottom. These
regions may represent secondary sites of interaction for MyD88
and TRIF and interestingly a previous study pointed to the CD
loop located on the bottom surface as a binding site for MyD88
[16]. The third group of mutants are those that make important
intra-chain contacts and are probably required for the stability of
the TIR domain fold. We have also assayed a number of mutant
receptors for signalling to both NFkB (a Mal directed target) and
IFNb (a TRAM target). The results (Table 3) show that mutations
on the whole have similar effects on both arms of the TLR4
pathway consistent with the Mal and TRAM adaptors binding to
the same or overlapping site on the activated receptor.
In addition to mutagenesis, studies with cell permeable blocking
peptides also provide support for the model proposed here.
Peptides corresponding to the BB-loop of TLR4 strongly inhibit
LPS induced responses mediated by both the TRAM and the Mal
adaptors [24]. According to our model this peptide would compete
with the BB loops in the receptor TIRs and prevent or disrupt the
formation of the homodimer. BB-loop peptides from Mal and
TRAM also inhibit LPS signalling, again affecting both arms of
the pathway [25]. This result is also consistent with our model as it
provides strong evidence that the BB-loops of Mal and TRAM
play a critical role in binding to the activated receptor. As the
peptides block both NFkB and IRF-3 directed responses this result
also indicated that the binding sites for the two adaptors overlap.
The same study also found that a BB-loop peptide from MyD88
Figure 4. Docking studies predict that the adaptors bind at the side of the TLR4 homodimer interface. The TLR4 protomers, represented as ribbon
diagrams are in green and cyan. Docked Mal and TRAM are represented as stick models and the 50 best docking solutions generated by GRAMM for
either Mal (A) or TRAM (B) have been superimposed upon one another. (C) High resolution complex of TLR4 dimer (green and cyan), Mal (pink) and
TRAM (yellow). The position of each BB loop is labelled.
doi:10.1371/journal.pone.0000788.g004
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Table 2. Potential structural impact of TLR4 TIR mutations.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mutation Structural justification for functional impact
YD674-675AA Loss of hydrogen bonding - structural destabilisation
FVI677-679AAA Buried – structural disruption of hydrophobic core
YSS680-682AAA Disruption of TLR4 TIR dimer formation
Q683A Possible interference with adaptor binding
K694A Disrupt favourable electrostatic interactions
NLE695-697AAA Disrupt favourable electrostatic interactions
EG698-699AA Possible interference with adaptor binding
VP700-701AA Possible interference with adaptor binding
C706S* Buried – structural disruption of hydrophobic core
LCL705-707AAA Buried – structural disruption of hydrophobic core (poor expression)
HYR708-710AAA Disrupt favourable electrostatic interactions and dimerization
DFI711-713AAA Loss of hydrogen bonding, loss of favourable electrostatic interactions, disruption of dimer formation
P714H* Structural distortion and disruption of dimer formation
PGV714-716AAA Disruption of TLR4 TIR dimer formation
I718A Disruption of TLR4 TIR dimer formation
II722-723AA Possible interference with adaptor binding
H724A Possible interference with adaptor binding
E725A Disrupt favourable electrostatic interactions
G726C* Buried – structural disruption of hydrophobic core
GF726-727AA Buried – structural disruption of hydrophobic core
H728D* Possible interference with adaptor binding
K729A Disrupt favourable electrostatic interactions
VIV733-735AAA Buried – structural disruption of hydrophobic core
VVS736-738AAA Buried – structural disruption of hydrophobic core
QH739-740AA Loss of hydrogen bonding - structural destabilisation
IQ742-743AA Loss of hydrogen bonding - structural destabilisation
SR744-745AA Disruption of TLR4 TIR dimer formation
C747S* Disruption of TLR4 TIR dimer formation
YE751-752AA Disruption of TLR4 TIR dimer formation
I753A Possible interference with adaptor binding
Q755A Disruption of TLR4 TIR dimer formation
TW756-757AA Loss of hydrogen bonding - structural destabilisation
Q758A Possible interference with adaptor binding
FL759-760AA Possible interference with adaptor binding
R763A Possible interference with adaptor binding
GI765-766AA Buried – structural disruption of hydrophobic core
IFI767-769AAA Buried – structural disruption of hydrophobic core
K773A Disrupt favourable electrostatic interactions
EK775-776AA Possible interference with adaptor binding
QQ781-782AA Loss of hydrogen bonding – structural destabilisation
RL787-788AA Possible interference with adaptor binding
TY793-794AA Possible interference with adaptor binding
EWE796-798AA Disrupt favourable electrostatic interactions
DS799-800AA Reduction in expression levels
G803A Possible interference with adaptor binding
HI805-806AA Possible interference with adaptor binding
FWR807-809AAA Possible interference with adaptor binding
RR809-810AA Possible interference with adaptor binding
RLR810-812AAA Possible interference with adaptor binding
LR811-812AA Possible interference with adaptor binding
L815A Buried – structural disruption of hydrophobic core
Y794STOP Disruption of electrostatic surface and possible interference with adaptor binding
R809STOP Poor expression
W821STOP Possible interference with adaptor binding
Mutants displaying,75% wild-type activity in NFkB reporter assays were interpreted for their potential impact on TLR4 TIR structure and used to guide docking studies.
Data obtained from Ronni et al [23] except for those marked with an asterisk which were assayed as part of this study (see also Table 3).
doi:10.1371/journal.pone.0000788.t002
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inhibited signalling by LPS. This finding suggests that initial
binding of the Mal or TRAM adaptors creates a new surface for
association of MyD88 and TRIF with determinants contributed by
both the receptor and the adaptor TIRs, possibly involving the
bottom surface of the homodimer.
A third line of evidence in support of the model comes from
studies of tyrosine phosphorylation. Mal is phosphorylated by the
Bruton tyrosine kinase at positions 86, 106 and 187 and
substitution of tyrosine with phenylalanine at positions 86 and
187 impairs LPS mediated signalling to NFkB [26]. As shown in
Figure 5, Tyr86 is located close to the BB-loop and should
interfere with binding of Mal to TLR4. In our complex Tyr86
makes an interaction that buries 33.0 A˚2 of surface. Interestingly,
co-immunoprecipitation experiments indicate that the phospho
forms of Mal do not bind to TLR4.
DISCUSSION
The structural modelling and functional studies presented here
provide strong support for theoretical models of signal trans-
duction by TLR4 and other Toll family receptors [12]. In this
view, stimulus induced dimerization of the receptor extracellular
domains leads to concerted protein conformational changes that in
turn lead to self-association or rearrangement of the receptor TIRs
thereby creating a new molecular surface for the recruitment of
signalling adaptor proteins. In our model of the TLR4 homodimer
the interface has extensive interactions involving the BB loops of
the two subunits. The conserved proline residue will confer a rigid
conformation on the BB-loop and substitution by other residues
would cause considerable distortion in the geometry of the
homodimer interface. Another important conclusion of this study
is that the receptor TIRs associate with a 2-fold axis of symmetry.
This implies that the linkers between the membrane and the TIR
domains have rotational flexibility. This seems plausible as the
linkers are fairly long (about 20 amino acids) and contain glycine
residues that can adopt a wider range of dihedral angles than the
chiral amino acids. Another interesting feature of the TLR4 dimer
is the flat but slightly curved surface predicted to form the top or
membrane proximal surface of the structure (Figure 3B). This
architecture is seen in other proteins that interact with membrane
surfaces, for example the BAR domain of amphiphysin [27].
Our model also predicts that Mal and TRAM bind to the same
region in the TLR4 dimer interface. This explains why cell
permeable blocking peptides compete out both Mal and TRAM
directed responses simultaneously [24,25]. However, the model
does not resolve the question of whether a single activated receptor
dimer can stimulate both the Mal and TRAM directed pathways
Table 3. Summary of effects of mutation on NFkB and IFN-
b activation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TLR4 Mutation NFkB activation IFN-b activation
E698K S S
C706S RS nd
P714H NS NS
G726C NS nd
H728D RS RS
Q743A S S
C747S RS nd
W757A S RS
K776D S S
C706S/C747S NS nd
All mutations were tested in at least three independent assays. S = signals
comparative to wild-type, RS = reduced signal compared to wild-type, NS = no
signalling, nd = not determined.
doi:10.1371/journal.pone.0000788.t003
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Table 4. Residues that produce strong interactions (DASA.40 A˚2) in the interface of the TLR4 dimer-Mal complex.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Residue Number Residue type TLR4 Chain DASA (A˚2) Residue Number Residue type Mal Chain DASA (A˚2)
683 Gln A 91.3 78 Gly C 65.3
685 Glu A 48.9 81 Arg C 74.0
740 His A 59.6 82 Trp C 57.4
743 Gln A 76.7 83 Ser C 111.9
778 Leu A 126.1 85 Asp C 84.0
780 Arg A 53.2 124 Thr C 62.9
669 Arg B 46.5 130 Val C 41.8
671 Glu B 85.9 131 Ser C 41.2
724 His B 116.0 134 Cys C 42.9
728 His B 88.3 135 Gln C 95.0
755 Gln B 69.3 138 Ser C 52.5
757 Trp B 175.2 161 Met C 46.9
824 Glu B 161.4 165 Leu C 116.0
166 Thr C 65.5
167 Glu C 122.2
168 Ala C 58.9
172 Glu C 80.7
187 Tyr C 53.5
221 Glu C 46.7
doi:10.1371/journal.pone.0000788.t004..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
TLR4 TIR Signalling
PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e788
simultaneously or whether adaptor engagement is mutually
exclusive, something that would require positive cooperativity.
Whilst we are currently addressing this question, it is clear
however, that each activated receptor will have two symmetry
related adaptor binding sites so in principle either hypothesis is
feasible.
Previous studies have attempted to model the interactions of
Mal and MyD88 with TLR4 and TLR2 [16]. However, these
used monomeric receptors in the modelling process. It is now
widely believed that receptor activation leads to ligand induced
dimerization [12]. Consequently our current studies have
modelled the activated TLR4 receptor as a dimer and are
therefore likely to be more physiologically relevant. This may
explain the altered orientation of Mal binding compared to the
previous study. Our observations are however broadly consistent
with the earlier predicted location of a binding site for MyD88 on
TLR4. Further, our work suggests that initial binding of the
‘bridging adaptor’ proteins may contribute to formation of an
additional surface for secondary adaptor binding.
The predicted adaptor/receptor binding surface is extensive
and is contributed to by many residues from both the receptor and
the adaptors. This may explain why many mutations in the
receptor TIR only partially impair signalling (see Tables 2 and 3
and ref [23]). Changing a single favourable receptor-adaptor
contact might result in a decrease in affinity of the complex but
would not abolish function completely.
The docking results suggest that Mal binds the TLR4
homodimer with a closer proximity and greater number of direct
contacts than TRAM does (Tables 4 and 5). This may suggest
a higher affinity for Mal binding and would perhaps explain why
TRAM is not subjected to such high levels of cellular regulation
and also why Mal/MyD88 pathways trigger early NF-kB
expression, but TRAM/TRIF signalling results in late NF-kB
expression. Moreover, phosphorylation by Bruton tyrosine kinase
of Mal at Tyr86, a residue predicted to interact strongly with the
TLR4 homodimer may render Mal-TLR4 interaction sterically
unfeasible in addition to facilitating SOCS-1 mediated Mal
polyubiquitination and degradation [28]. Interestingly, the
equivalent residue in TRAM is Phe78 suggesting that the binding
between TRAM and the receptor dimer may be a relatively
weaker hydrophobic interaction.
Two other recently published results concerning Mal are also of
interest in the context of this model. Firstly, Miggin et al. [29] have
shown that Mal is cleaved at position 198 by the cysteine protease
caspase 1 and that this processing is required for Mal to function in
signalling by both TLR2 and TLR4. The cleavage releases a 4 kDa
fragment from the C-terminus of Mal (see Figure 2 and 5)
corresponding to the ‘EE’ loop and the last (E) a-helix of the TIR
fold. As shown in Figure 5, the site of proteolysis is on the surface
opposite the BB-loop and thus should not affect binding of Mal to
the receptor dimer. One explanation for this finding might be that
in the absence of caspase cleavage MyD88 cannot be recruited
into the postreceptor complex by Mal. Plausibly MyD88 might
displace the ‘E’ helix from Mal and bind into the cleft that is
exposed (Figure 5A–D). The second study concerns a variant of
Mal, Ser180Leu, which is common in the human population.
When heterozygous this polymorphism protects against a range of
microbial infections and cell based assays show that the mutation
significantly impairs signalling by both TLR2 and TLR4 [30]. In
our model of Mal this residue is buried in the structure but would
be exposed after cleavage with caspase 1 (Figure 5C, D). Thus it is
possible that the observed loss of function associated with
Ser180Leu is caused by a defect in recruitment of MyD88 to
caspase-1 cleaved Mal. With the replacement of serine by a large,
hydrophobic leucine residue introducing an unfavourable in-
teraction in the caspase-1 cleaved adaptor.
In conclusion, the current study provides a basis for future
structural and functional studies of TLR4 activation. A long term
objective is to carry out experimental structural analysis of
activated membrane receptor complexes of TLR4 using low
resolution techniques such image reconstruction of electron
micrographs as well as protein crystallography.
MATERIALS AND METHODS
Molecular modelling
The amino acid sequences and three dimensional structures of the
homologous proteins used as templates for comparative modelling
were obtained from the Protein Data Bank (http://www.rcsb.org/
Table 5. Residues that produce strong interactions (DASA.40 A˚2) in the interface of the TLR4 dimer-TRAM complex.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Residue Number Residue type TLR4 Chain DASA (A˚2) Residue Number Residue type TRAM Chain DASA (A˚2)
669 Arg A 108.3 73 Ala D 48.3
671 Glu A 77.7 74 Glu D 101.0
724 His A 101.9 75 Glu D 133.7
728 His A 106.2 119 Arg D 52.8
755 Gln A 130.1 130 Asn D 73.5
757 Trp A 155.7 153 Phe D 86.3
758 Gln A 43.4 155 Thr D 74.7
760 Leu A 78.1 156 Ser D 107.1
819 Lys A 60.1 157 Leu D 49.3
821 Trp A 50.8 159 Asn D 152.1
822 Asn A 90.3 160 Ser D 51.0
824 Glu A 68.0 163 Arg D 147.9
743 Gln B 90.1 164 Gln D 118.6
780 Arg B 123.7 233 Phe D 71.7
235 Ala D 45.3
doi:10.1371/journal.pone.0000788.t005..
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pdb). Initial alignments between target protein and its templates
were obtained using the program FUGUE [31]. FUGUE
produces alignments by comparison of sequence profiles with
structural profiles of homologous protein families taken from the
HOMSTRAD database [32].
Models were produced using the program MODELLER [33].
MODELLER produces comparative models satisfying spatial
restraints with simultaneous optimization of CHARMM energies
[34]. This method uses conjugate gradients and molecular
dynamics with simulated annealing [33]. The form of the spatial
restraints was obtained by statistical analysis of the relationship
between pairs of homologous structures from a database of
sequence alignments for 416 proteins of known 3D structure in
105 families. Comparative models were verified by the validation
programs PROCHECK [35], VERIFY3D [20] and JOY [36].
The alignments were then manually modified as required and the
modelling and validation process repeated. The process of
modelling, validation and realignment was repeated until models
with good geometry and conformation had been obtained.
Contact residues in the TLR4 homodimer and docked
complexes were defined as the residues that possessed an interface
solvent accessible surface area (ASA) that decreased (DASA) by
more than 1 A˚2 on complexation [37]. The ASA was calculated
using the Lee and Richards algorithm [38] developed by
Richmond [39]. HBPLUS was used for hydrogen bond definition
[40]. Electrostatic interactions were calculated using an in house
program (ELECINT, R.N. Miguel, unpublished) using a dielectric
constant distance dependent for electrostatic field calculation and
pH = 7.4 for the calculation of charges of side chain atoms of
charged residues using the Henderson-Hasselbalch equation.
Figure 5. Modelling suggests a molecular explanation for the caspase 1 dependence of Mal and the malfunctional human polymorphism
Ser180Leu. The models are shown as van der Waal surface representations. (A) Side view showing the position of the BB loop (green) and the
phosphorylated tyrosine, Tyr86. In the complex this part of Mal forms the interface with TLR4. The position of the a-E helix (red) which is cleaved out
by caspase 1 is shown on the opposite surface to the BB loop. (B) Back view of Mal (rotated 90u to the right relative to (A)). (C), (D) Mal with the a-E
helix removed highlighting the deep groove created and the exposed position of the otherwise buried Ser180 residue (yellow).
doi:10.1371/journal.pone.0000788.g005
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Protein docking and binding site prediction
Low resolution protein-protein docking was carried out using
Global Range Molecular Matching (GRAMM) methodology [41].
GRAMM methodology is an empirical approach to smoothing the
intermolecular energy function by changing the range of the atom-
atom potentials. Low resolution docking is useful for determining
possible relative positions of the two proteins in the complex. High
resolution protein-protein docking was performed by the program
PyDock [22]. PyDock is a method for rigid-body protein-protein
docking. It explores either FTDOCK or ZDOCK methods to
generate conformations of complexes and uses a scoring function
that applies electrostatics and desolvation energies to select the best
solutions.
The FPSPD program [42] was used for the identification of
functional sites. FPSPD utilises environment-dependent substitu-
tion tables and evolutionary trace analysis to identify residues from
a structurally-aligned homologous family of proteins that are
unusually highly conserved. Solvent accessibility calculations are
used to estimate the probability of residues and molecular patterns
being directly involved in functional interactions. The three-
dimensional structure is used to estimate the borders of the
functional patterns.
Plasmids and reagents
pcDNA3TLR4, pcDNA3CD14, pEFIREMD2, pNFBluc and
pRantes were as previously described [43,44]. Lipopolysaccharide
(Escherichia coli serotype 0127;B8) was obtained from Sigma;
recombinant human TNF and IFN were from R&D Systems.
The phRGTK plasmid (Promega) was used as a transfection
control. Site-directed mutagenesis was performed on
pCDNA3TLR4 using the Stratagene Quikchange procedure.
Cell culture, transfections and luciferase assay
HEK293 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, 100 mg/ml
penicillin/streptomycin and 2 mM L-glutamine at 37uC and 5%
CO2. Cells were seeded at 10
5 ml21 24 hr prior to transfection
using Polyfect (Qiagen). Cells were stimulated 48 hrs post
transfection. The Dual-Glo system from Promega was used for
luciferase assays. Luminescence readings were obtained using
a Lumister luminometer (BMG Labtech).
SUPPORTING INFORMATION
Table S1 Joy alignment key
Found at: doi:10.1371/journal.pone.0000788.s001 (0.06 MB
DOC)
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